Aspira Women's Health Faces Delisting Concerns
Ticker: AWHL · Form: 8-K · Filed: Jul 5, 2024 · CIK: 926617
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Aspira Women's Health is on the chopping block for delisting.
AI Summary
Aspira Women's Health Inc. filed an 8-K on July 5, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of July 1, 2024. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.
Why It Matters
This filing indicates potential issues with Aspira Women's Health Inc.'s continued listing on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading and investor confidence.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Vermillion, Inc. (company) — Former Company Name
- Ciphergen Biosystems Inc (company) — Former Company Name
- Abiotic Systems (company) — Former Company Name
- July 01, 2024 (date) — Date of earliest event reported
- July 5, 2024 (date) — Filing Date
FAQ
What specific listing rule or standard has Aspira Women's Health Inc. failed to satisfy?
The filing states a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard in the provided text.
What is the effective date of the delisting concern?
The earliest event reported is July 01, 2024, indicating the date as of which the company is potentially not meeting listing requirements.
When was this 8-K form filed with the SEC?
The 8-K form was filed on July 5, 2024.
What were some of Aspira Women's Health Inc.'s previous names?
The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.
Where is Aspira Women's Health Inc. incorporated and headquartered?
The company is incorporated in Delaware and headquartered in Austin, Texas.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 13.9 · Accepted 2024-07-05 16:30:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH The Nasdaq Stock Mark
- $35 million — ted Securities was below the minimum of $35 million required for continued listing on the N
- $35.0 million — pany's common stock must meet or exceed $35.0 million for a minimum of 10 consecutive busines
- $2.5 million — ng its stockholders' equity to at least $2.5 million. In the event the Company does not re
Filing Documents
- awh-20240701.htm (8-K) — 38KB
- 0000950170-24-081880.txt ( ) — 152KB
- awh-20240701.xsd (EX-101.SCH) — 25KB
- awh-20240701_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 1, 2024, Aspira Women's Health Inc. (the "Company") received written notice (the "Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company's minimum Market Value of Listed Securities was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until December 30, 2024 (the "Compliance Date"), to regain compliance with the MVLS Requirement. If the Company regains compliance with the MVLS Requirement, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. To regain compliance with the MVLS Requirement, the market value of the Company's common stock must meet or exceed $35.0 million for a minimum of 10 consecutive business days during the 180-day grace period ending on the Compliance Date, unless the Staff exercises its discretion to extend this ten consecutive business day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its listed securities. The Company may also, if appropriate, consider other options to regain compliance with Nasdaq's continued listing standard such as by increasing its stockholders' equity to at least $2.5 million. In the event the Company does not regain compliance prior to the Compliance Date, the Company will receive written notification that its securities are subject to delisti
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 5, 2024 By: /s/ Nicole Sandford Nicole Sandford, Chief Executive Officer